Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on July 29, 2008
JNCI Journal of the National Cancer Institute 2008 100(15):1046-1047; doi:10.1093/jnci/djn241
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
100/15/1046    most recent
djn241v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Hershman, D. L.
Right arrow Articles by Neugut, A. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hershman, D. L.
Right arrow Articles by Neugut, A. I.
Related Collections
Right arrowRelated Articles in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press.

EDITORIALS

Anthracycline Cardiotoxicity: One Size Does Not Fit All!

Dawn L. Hershman, Alfred I. Neugut

Affiliations of authors: Department of Medicine and Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons and Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY (DLH, AIN)

Correspondence to: Alfred I. Neugut, MD, PhD, Division of Medical Oncology, Columbia University Medical Center, 722 West 168th Street, Room 725, New York, NY 10032 (e-mail: ain1@columbia.edu).

The first 10% of the full text of this article appears below.

The oncology community has known for more than 30 years that anthracycline-containing chemotherapy improves disease-free and overall survival in patients with breast cancer (1). Despite this, physicians are often reluctant to use it in certain "high-risk" groups, such as the elderly, due to concerns over the risk of short- and long-term cardiotoxicity. Although the risk of cardiotoxicity is dose dependent (2,3), it has been hard to predict which patients are at greatest risk for developing complications from treatment.

Randomized clinical trials are excellent for establishing the efficacy of new therapies by comparing experimental and standard therapies. However, many patients do not qualify for the rigorous entry criteria of most trials, and, thus, . . . [Full Text of this Article]

Funding


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Articles in JNCI

New Insight Into Epirubicin Cardiac Toxicity: Competing Risks Analysis of 1097 Breast Cancer Patients
Marianne Ryberg, Dorte Nielsen, Giuliana Cortese, Gitte Nielsen, Torben Skovsgaard, and Per Kragh Andersen
J Natl Cancer Inst 2008 100: 1058-1067. [Abstract] [Full Text] [PDF]

IN THIS ISSUE
J Natl Cancer Inst 2008 100: 1045. [Extract] [Full Text] [PDF]